Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Legend Biotech has reported Total Non-Current Liabilities for 7 years, with the latest figure at $95.2 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 72.95% year-over-year to $95.2 million; the trailing twelve-month figure through Dec 2025 stood at $95.2 million (down 72.95% YoY), and the FY2025 full-year result was $95.2 million, down 72.95% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $95.2 million, down from $268.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $388.9 million in Q2 2025, with the low at $262860.0 in Q1 2021.
• Historically, Total Non-Current Liabilities has averaged $291.4 million across 5 years, with a median of $323.4 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 143102.85% — and 2025, when it sank 72.95%.
• Legend Biotech's Total Non-Current Liabilities stood at $124.3 million in 2021, then surged by 132.36% to $288.9 million in 2022, then soared by 31.83% to $380.8 million in 2023, then fell by 7.59% to $351.9 million in 2024, then slumped by 72.95% to $95.2 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $95.2 million (Q4 2025), $268.1 million (Q3 2025), and $388.9 million (Q2 2025), per Business Quant data.